Oseltamivir reduces duration and complications of influenza
the ONA take:
According to a new study published in the journal The Lancet, researchers at the University of Michigan, the University of Alabama, and the London School of Hygiene and Tropical Medicine have found that oseltamivir, a neuraminidase inhibitor, decreases the duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
For the meta-analysis, researchers identified clinical trials conducted between 1997 and 2001. The studies included over 4,300 patients with more than half being treated with oseltamivir for influenza.
Results showed that when patients took oseltamivir 75mg twice daily within 36 hours of developing at least two flu symptoms, oseltamivir decreased the duration of the flu by 21%.
Patients who took oseltamivir experienced symptom alleviation at 98 hours versus 123 hours for those who took placebo.
In addition, researchers found that 4.9% of those who took oseltamivir had respiratory complications compared with 8.7% of those who took placebo. Oseltamivir was also shown to reduce hospital admissions by 63%. In regard to safety, oseltamivir increased nausea and vomiting, but did not cause more neurological or psychological disorders than placebo.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|